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Abstract 
Background and Aim: This study is conducted to evaluate whether 
in-vitro maturation of immature oocytes retrieved from stimulated cycles can 
help to increase the number of embryos available for transfer and whether 
transfer of embryos derived from in-vitro matured oocytes would contribute 
to better clinical outcomes of poor responder patients in ovarian stimulated 
cycles. 
PatientsandMethods: The present study was approved by the ethics 
committee in the College of Medicine,University of Sulaimani, Sulaimani, 
Kurdistan Government region, Iraq. Written informed consent was obtained, 
in which patients informed and understood to share the outcomes of their 
cycles for research purposes. The present study includes 92 poor responder 
cycles for intra cytoplasmic sperm injection. It comprises three and less 
mature oocytes (Metaphase II stage) with at least one immature oocyte 
(Metaphase I and Prophase I stage) which are retrieved after follicle 
aspiration and cycles are split into two groups control group (n=51), in which 
only mature oocytes are used, and in-vitro maturation (IVM) group (n=41) 
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where the immature oocytes are matured in-vitro and used, then the 
outcomes are compared. In in-vitro maturation group, oocytes are classified 
based on nuclear maturation status in to mature (Metaphase II) and immature 
oocytes (Metaphase I and Prophase I). The rates of in-vitro maturation, 
fertilization, and high-quality embryos are compared. 
Results: Between the control group and in-vitro maturation group, no 
differences are observed as far as the implantation rate is concerned (12.5%, 
12.5% respectively, p >0.05), while the in-vitro maturation group has a 
higher number of transferred embryos than the control group (1.54±1.12, 
1.1±0.9, respectively, p<0.05), a higher pregnancy rate (21.9%, 18.9%, 
respectively, p<0.05), with a lower embryo transfer cancellation rate (21.9%, 
27.45% respectively, p<0.05).  In in-vitro maturation group, immature 
oocytes have lower fertilization rate (40.47% versus 58.33%) with (p <0.05), 
higher high-quality embryos (64.7% versus 51.43%) with (p< 0.05) and no 
difference between Metaphase I and Prophase I in the rates of in-vitro 
maturation, fertilization and high-quality embryos.  
Conclusion: The results show that human immature oocytes recovered from 
stimulated cycles can be matured, fertilized and developed in-vitro but they 
have lower fertilization rate than the in-vivo matured oocytes. Embryos 
derived from in-vitro matured oocytes may contribute to the better outcome 
in poor responder cycles. 
 
Keywords: In-vitro maturation, immature oocytes, poor responder 
 
Introduction 
Since the momentous birth of Louise Brown in 1978, the focus of 
assisted reproductive technology (ART) has been on securing numerous 
mature oocytes prior to their removal from the ovary (Pellicer et al., 1989). 
This procedure allows optimal in-vivo oocyte maturation prior to their 
retrieval, challenging the laboratory to accomplish fertilization and early 
embryonic division before their transfer and possible implantation to the 
endometrial cavity.  The past decades of refinements have been evolved with 
the oocyte retrieval process moving toward a more simplified, minimally 
invasive transvaginal ultrasound-guided aspiration combined with extremely 
technological advanced fertilization procedures, such as intracytoplasmic 
sperm injection (ICSI) (Russell et al., 1997). Laboratory culture techniques 
examine a variety of conditions including different media preparations with 
or without serum supplementation, different media enhancing additives, and 
the controversial use of co-culture techniques (Magli et al., 1996). Clinically, 
ovulation induction protocols focus on enhancing recruitment of the cohort 
of follicles and synchronizing their development by down-regulation of the 
central axis using gonadotrophin-releasing hormone (GnRH) agonists ( 
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Meldrum et al., 1989). All of these factors have added to the ability to offer 
in-vitro fertilization (IVF) to numerous patients with multiple diagnoses with 
gradually improving clinical pregnancy rates. A process introduced several 
years ago in animal studies utilized in-vitro oocyte maturation as a supply of 
mature oocytes;  In 1935, Pincus and Enzmann  reported that immature 
rabbit oocytes removed from their natural ovarian environment are capable 
of undergoing spontaneous maturation and fertilization in-vitro(Pincus and 
Enzmann, 1935). Similar observations were later reported in human beings 
by Edwards in 1965.  This practice was then introduced into human clinical 
trials during the early days of IVF (Edwards et al., 1965; Tsuji et al., 1985). 
This procedure has been successful in producing live born offspring in 
animals (Keskintepe et al., 1994), and in humans (Russell et al., 1997).  The 
challenge with human in-vitro oocyte maturation is to provide optimal 
conditions for in-vitro maturation by mimicking the micro-endocrine 
environment of the developing follicle to enable the immature oocyte to 
achieve nuclear and cytoplasmic maturation. Once oocyte maturation in- 
vitro is completed, fertilization and culture conditionsmust also be optimal 
prior to the transfer of embryos to the uterus for the implantation to take 
place (Smith et al., 2000) Under controlled ovarian stimulation, some of the 
collected oocytes are approximately 20% immature (Smith et al., 2000). 
These oocytes are usually discarded due to the possibility of abnormal 
embryonic development, or an increased rate of abortion. However, in cases 
of poor responders and in patients with an unsynchronized cohort of follicles, 
where the presence of immature oocytes is frequent after stimulation (Smitz 
and Cortvrindt, 1999), the use of immature oocytes for IVF is important in 
order to increase the number of embryos obtained in each cycle. Based on 
the assumption that oocyte maturity is a prerequisite for obtaining normal 
fertilization, attempts have been made both in mammals and in human to 
mature germinal vesicle (GV) which is prophase I oocytes and metaphase I 
(MI) oocytes in-vitro( Huang et al., 1999). 
 
Patients and methods 
Study Design 
The present study was approved by the ethics committee in the 
College of Medicine, University of Slemani, Slemani, Kurdistan 
Government Region, Iraq. Written informed consent was obtained, in which 
patients informed and understood to share the outcomes of their cycles for 
research purposes. The study included 92 poor-responder patients 
undergoing ICSI cycle, in which three and less M II oocytes and at least one 
immature oocyte (M I or P I oocyte) were retrieved after follicle aspiration in 
Dwarozh-IVF center between February 2010-July 2011.Cycles were divided 
into two groups, control group in which only mature oocytes are used 
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(control group, n= 51), and (IVM group, n= 41) the immature oocytes were 
also injected but after in-vitro maturation. The rates of embryo transfer 
cancellation (cycle with cancel transfer per total cycles), clinical pregnancy 
(presence of gestational sac with fetal heart beat visualized by ultrasound 4-6 
weeks after embryo transfer, implantation (total number of gestational sacs 
divided by the total number of embryos transferred) and miscarriage 
(spontaneous loss of a pregnancy before 24 weeks of gestation) were 
compared. In IVM group oocytes are classified into mature (MII stage) 
oocytes and immature oocytes (MI and P I). Rates of in-vitro nuclear 
maturation (oocytes which complete meiosis I and enter metaphase of 
meiosis II per total immature oocytes were subjected to in-vitro maturation), 
fertilization (two pronuclei were seen in the oocyte after 16-18 hours of 
ICSI) and, high-quality embryos (either 4–6 cells on day 2 or 8–10 cells on 
day 3 of development, less than 15% fragmentation, symmetric blastomeres, 
absence of multinucleation, colourless cytoplasm with moderate granulation 
with no inclusions, absence of perivitelline space granularity and absence of 
zonapellucidadysmorphism) were evaluated. 
 
Ovarian Stimulation 
Ovarian stimulation had been done by gynecologist which started 
with baseline transvaginal ultrasonography (Siemens, Sonoline G20, 
Siemens Medical Solutions USA, Inc.) to document antral follicular count > 
6 follicles and blood testing in the second day of the cycle for FSH (3.9-12 
mIU/ml), E2 (18-147pg/ml), LH (1.5-8 mIU/ml), and P4 (≤ 0.25-0.54ng/ml) 
were performed with (miniVIDAS, bioMerieux, 06267 M, France) with 
using enzyme immuno assay competition method with a final florescent 
detection for E2, P4 and enzyme immuno assay sandwich method with final 
fluorescent detection for FSH and LH.   In all patient short agonist protocol 
was used for induction of the ovaries which start GnRH agonist (Decapeptyl, 
Ferring GmbH, Germany) on day 2 and gonadotropins (Gonal-f, 
LaboroteriesSerono S.A, Switzerland; Fostimon, IBSA, Lugano 3, Suisse; 
Puregon, Schering-Plough, NV.Organon, Oss, Netherlands; Menegon, 
Ferring GmbH, Germany; and Merional, IBSA, Lugano 3, Suisse)  Follow 
up of induction is started using transvaginal ultrasound (G20, Siemens, 
United States) and E2 and when ultrasound show ≥ 4 follicles with diameters 
of 16-17mm and E2 >500pg/ml,  patients are administered a hCG ( 
Choriomon, IBSA, Lugano 3, Suisse; Ovitrelle, IndustriaFarmacuticaSerono 
S.P.A, Bari, Italy). This medication contained the pregnancy hormone, hCG, 
which functions similarly to LH is an important hormone that helps in 
maturation of the ova, to be ready for fertilization, and stimulates ovulation 
(Holzer et al., 2006).  
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Oocyte Retrieval 
Oocyte retrieval had been done by gynecologist 34-36 hours 
following hCG administration, Oocyte retrieval was performed by vaginal 
ultrasound- guided puncture using 16 gage 35cm double lumen aspiration 
needle (William A.Cook, Australia pty Ltd.) with negative pressure 20 
mmHg under intravenous general anesthesia. Follicular fluid aspirated into 
tube containing aspiration media and heparin (Ferticult Aspiration, Fertipro 
N.V, Belgium), then the oocyte-cumulus complex was collected under stereo 
microscope (Nikon, SMZ 1500, Tokyo, Japan) and washed with flushing 
media (Ferticult flushing, Fertipro N.V, Belgium) then placed inside IVF 
media (Ferticult IVF, Fertipro N.V, Belgium)in incubator 37 ˚C and 6% CO2 
for 1-2 hours. 
 
Denudation of The Oocytes 
 Removal of the surrounding cumulus cells is accomplished by a 
combined enzymatic exposure to hyaluronidase enzyme in HEPES-buffered 
medium containing 80 IU/ml (Hyase, Fertipro N.V, Belgium) and 
mechanical treatment. The oocytes are repeatedly aspirated stepwise through 
a pasteur pipettes with an inner diameter of 290µm and 135µm (Ez-strip, 
Research Instruments Ltd, United Kingdom); the procedure was carried out 
under a stereo dissecting microscope (Nikon, SMz1500, Tokyo, Japan).  
Each oocyte was then examined under the microscope to assess the 
maturation stage and its integrity. Metaphase II (MII) was assessed 
according to the absence of the germinal vesicle (GV) and the presence of an 
extruded polar body see micrograph (3.1) metaphase I (MI) was assessed 
according to the absence of both (GV) and extruded polar body see 
micrograph (3.2), and prophase I (PI) when (GV) was obvious in the absence 
of extruded polar body see micrograph (3.3) (Dickmann, 2005).    
 
In-Vitro Maturation 
Immature oocytes of patients (MI and PI) were placed in SAGE IVM 
medium (Cooper Surgical, Trumbull, CT), which contain basic media 
component (sodium chloride, potassium chloride, sodium bicarbonate, 
sodium pyruvate, glucose, phenol red and gentamycin), essential amino 
acids, non-essential amino acids, vitamins, and plasma protein fractions with 
the addition of 75 mlU/mL of FSH and 75 mlU/mL of LH according to the 
manufacturer’s recommendation. The time at which these immature oocytes 
were placed in IVM media considered as time zero for IVM.  After 
approximately 24 h of incubation in IVM medium, the oocytes were re-
evaluated; those oocytes that achieved maturation as mentioned earlier 
underwent second day injection with new prepared semen sample, while 
those which remained immature were discarded. 
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Sperm Preparation 
The semen collected by masturbation in all cycles; then allowed to be  
liquefy for 15-30 minutes. After liquefaction analysis was done with Makler 
chamber (PolymedcoInc., Yorktown, NY) using phase contrast microscope 
(Olympus, BX41, Tokyo, Japan) according to WHO criteria. The semen was 
prepared using colloidal silica density gradient centrifugation (Sil-select 
Stock, Fertipro N.V, Belgium)as recommended then kept inside incubator 
37˚C until the time of ICSI.   
 
ICSI Procedure 
A drop of prepared sperms were placed in a ICSI dish (Nunc A/S, 
Denmark), sperms are aspirated with the injection pipette and transferred to 4 
µl droplet of polyvinylpyrrolidone solution which is a viscous synthetic 
polymers (PVP, Fertipro N.V, Belgium) for immobilization.(Brooks et al., 
2000).Active spermatozoa must first be immobilized; this is accomplished by 
gently lowering the tip of the pipette so as to compress the mid region of the 
sperm flagellum against the bottom of the dish, then it is drawn into the 
injection pipette from its tail  (Brooks et al., 2000), meanwhile the oocytes 
were placed in 5 µl droplets of Flushing medium which was covered by 
lightweight mineral oil (Ferticult Mineral oil, Fertipro N.V, Belgium) in 
order to maintain stable temperature, osmolality and pH (Miller et 
al.1994).ICSI was done as in (Nagy et al., 1995), and was carried out on the 
heated stage (37°C) of an inverted microscope (Integra Ti, R.I., Olympus, 
IX51/IX70, Tokyo, Japan) 40 h after HCG trigger for MII-stage retrieved 
oocytes and 64 h after HCG trigger for immature oocytes that had undergone 
nuclear maturation. After injection, the oocytes were washed and stored in 
25 µl micro drops of culture medium under oil in a culture dish. They were 
kept in an incubator at 37°C in an atmosphere of 6% CO2 for 16-18 hours.  
 
Assessment of Fertilization, Embryo Quality and Embryo Transfer 
At 16–18 h after microinjection, the oocytes were checked for 
survival and fertilization. The numbers and aspects of polar bodies and 
pronuclei are recorded. The criteria for normal fertilization are the presence 
of two clearly visible pronuclei. Embryo cleavage and the quality are 
evaluated 2 days after ICSI (Nagy et al., 1994). 
Embryo quality was evaluated under an inverted microscope. The 
following parameters were recorded: (i) the number of blastomeres; (ii) the 
fragmentation percentage; (iii) variation in blastomere symmetry; (iv) the 
presence of multinucleation; and (v) defects in the zonapellucida and the 
cytoplasm. High-quality (grade A) embryos were defined as those having all 
of the following characteristics: either 4–6 cells on day 2 or 8–10 cells on 
day 3 of development, less than 15% fragmentation, symmetric blastomeres, 
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absence of multinucleation, colourless cytoplasm with moderate granulation 
with no inclusions, absence of perivitelline space granularity and absence of 
zonapellucidadysmorphism. Embryos lacking any of the above 
characteristics are considered as low quality (de Almeida et al., 2010). 
For each couple, one to three embryos were transferred for female 
age ≤ 35 years old and more than three embryos for female age > 35 years 
old, if available. Embryo transfer was cancelled when there were no embryos 
available, when patients in each group had complete fertilization failure or 
the embryos failed to divide or embryo arrested division. In the IVM group, 
priority for transfer was given for embryos derived from MII oocytes.  
Embryo transfer was performed on day 2 or day 3, with the use of a Gynetics 
catheter (Gynetics Medical Products N.V, Lommel, Belgium), then cycles 
followed by serum B-HCG and Ultrasonography. Micrograph was taken with 
video camera 3mega pixel (WAT-221S, Olympus, Tokyo, Japan)   loaded 
over the inverted microscope connected to Cronus software (Research 
Instruments Ltd, United Kingdom) 
 
Assisted Hatching 
For increasing implantation assisted hatching (Cohen et al., 1990) 
which is a procedure done with using non-contact laser, type (Saturn 3, 
Research Instrument, UK) with 1480nm/ 400mW solid state diode laser. 
Pulse length range 0.1 – 2.0ms / 100-2000 microseconds, which cause 
thermolysis to the zonapellucida matrix and thinning of the zonapellucida. 
Assisted hatching is done for all patients (Brooks et al., 2000), 
 
Statistical Analysis 
 Results were expressed as mean ± standard deviation (SD) for 
numeric variables and percentages for categorical variables. Mean values 
were compared by Students t-test, and proportions were compared by chi-
squared test.   The results were considered to be significant at the (P < 0.05). 
Data analysis was carried out using the statistical analysis program 
(Statistical Package for Social Science SPSS) version 17. 
 
Results 
General Characteristics 
From 92 cycles included in this study, Female-factor infertility was 
found in 29 (31.52%) of the cycles, male-factor infertility was present in 24 
(26.08%) of the cycles, both-factor were responsible in 31(33.69%) of 
cycles, and unknown cause in 8 (8.7%) of them. Primary infertility was 
found in 73(79.35%) of the cycles and 13(14.13%) of them were their second 
attempt. The results showed no significant difference in age of female 
patients and years of infertility between IVM and control groups which was 
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(33.22±6.5, 33.63±6.2, p value > 0.05), (8.6±6, 6.6±3.3, P value > 0.05) 
respectively, but significant mean age for poor responder which was 33 years 
old.No significant difference in the number of retrieved oocytes which was 
(5.63±3.7, 4.73±2.1, P value < 0.05), were seen but the percentage of 
collected immature oocyte was significantly higher in IVM group than 
control group which was (65.68%, 43.98%, P <0.05) respectively as shown 
in table (3.1). 
Table (3.1): General Characteristics of Control and IVM Groups  
 
For the hormones in the second day of the cycle, the result showed 
significant lower E2 level in control group than the IVM group which was 
(38.3±15.3, 45.97±28.6, P value <0.05) and no significant difference in FSH 
and LH levels which were (7.1±4, 7.4±3.1, P value < 0.05) and (3.04±1.4, 
3.3±1.8, P value < 0.05) while the level of P4 showed significant differences 
which was higher in the IVM group than the control group (4.9±5.35, 
1.6±4.4, P value< 0.05) as shown in table(3.2). The levels of E2 in the day of 
HCG injection were significantly higher in the IVM group (1209.43±693.3) 
than the control group (1047.93±658.9) with (P value < 0.05) as shown in 
table (3.2). 
 
Nuclear Maturation Status and In-vitro Maturation: 
In IVM group, the overall in-vitro matured oocytes were compared to 
the in-vivo matured oocytes and the results indicate that the percentage of 
fertilized oocytes were significantly higher in in-vivo matured oocytes than 
in-vitro matured oocytes, which was (58.33%, 40.47% respectively; P < 
0.05), but high-quality embryos was significantly higher in in-vitro matured 
oocytes than the in-vivo matured oocytes, which was (64.7%, 51.43% 
respectively; P < 0.05) as shown in table( 3.3). 
  
General characteristics Control group N= 51 
IVM group 
N= 41 P value 
Female age 33.22 ± 6.5 33.63 ± 6.2 0.754 
Year of infertility 8.61 ± 6.1 6.65 ± 3.33 0.070 
Induction duration 11.76 ± 1.2 11.54 ± 1.5 0.769 
oocytes retrieved 4.73 ± 2.1 5.63 ± 3.7 0.394 
Immature retrieved oocytes 43.98% 65.68% 0.001 
Values are mean± SD or % 
SD= standard deviation 
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Table (3.3): Compared Results Between In-vivo and In-vitro Matured Oocytes Used In IVM 
Group. 
 
In IVM group 231 oocytes were retrieved, from these oocytes 64 
(27.7%) were in MII stage, 78 (33.76%) were in MI stage and 70 (30.3%) 
were PI stage; both PI and MI were subjected to in-vitro maturation. Results 
demonstrate that 42 (60%) of PI oocytes completed maturation in-vitro and 
51 (65.38%)  MI matured in-vitro, 36 (85.7%) and 48 (94.11%) respectively 
were injected from each and the difference in fertilization and high-quality 
embryos rates between PI and MI; statistically, the difference are not 
significant as shown in table (3.4). 
Table (3.4): Compared Results Between Immature Oocytes Prophase I and Metaphase I 
Using in the IVM Group. 
 
 
Figure (3.1) Nuclear Maturation Status of Retrieved Oocytes in IVM Group  
0,00%20,00%40,00%60,00%80,00%100,00%
Nuclear maturation status of the
retrieved oocytes in IVM group
27,70% 33,76% 30,30% 
MII
MI
PI
 
In-vitro matured 
oocytes (PI and MI). 
N=148 
In vivo matured 
oocytes (MII). 
N= 64 
P value 
In-vitro matured 93 (62.84%) -------  
injected 84 (90.32%) 60 (93.75%) 0.713 
Fertilized 34 (40.47%) 35 (58.33%) 0.004 
High-quality 
embryos 22 (64.7%) 18 (51.43%) 0.005 
PI= prophase I, MI= metaphase I, MII= metaphase II 
 PI N= 70 
MI 
N= 78 P value 
In-vitro matured 42/70 (60%) 51/78 (65.38%) 4.99       NS 
Injected 36/42 (85.7%) 48/51(94.4%) 0.062     NS 
Fertilized 13/36 (36.1%) 21/48 (43.75%) 0.369      NS 
High-quality 
embryos 9/13 (69.23%) 13/21 (61.9%) 0.664      NS 
PI= prophase I, MI= metaphase I 
European Scientific Journal November  2014 edition vol.10, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
204 
Fertilization and Embryo Quality 
ICSI was performed in 259 oocytes in both control and IVM groups. 
In IVM group, 144 ICSI was performed, 84(58.33%) of them were immature 
oocytes. From these, 36(25%) of them were derived from PI stage and 
48(33.33%) of them were from MI stage. The results indicate that 
fertilization rates were significantly higher for in-vivo matured oocytes when 
compared to in-vitro matured oocytes( 58.33%, 40.47% respectively; P < 
0.05) and percentage of high-quality embryos derived from in-vitro matured 
oocytes as micrograph:(3.6;3.10) (are higher than the in-vivo matured oocyte 
(64.7%, 51.43% respectively; P > 0.05) as shown in table (3.3). 
 
Figure (3.2) Compared Result Between Metaphase I and Prophase I Oocytes in IVM Group 
 
Embryo Transfer and Clinical Outcome 
Embryo transfer was performed at day 2 and/or day 3, 14(43.8%) of 
IVM group and 24(64.9%) of control group with assisted hatching. The 
number of transferred embryos are significantly higher in IVM group than 
the control group (1.54 ± 1.12, 1.10 ± 0.88 respectively; P < 0.05). 
Table (3.5): Comparing number of embryo obtained between control and IVM group 
 
0%
50%
100%
In vitro matured
Injected
Fertilized
High-quality embryos
60% 
85,70% 
36,10% 
69,23% 
65,38% 
94,40% 
43,75% 
61,90% 
MI N= 78
PI  N= 70
 Control group IVM group 
No. of patients 51 41 
No. of retrieved oocytes 241 231 
Mature oocytes 115 64 
Immature oocytes 106 148 
No. of injected oocytes 115 
144 (60 from in-vivo mature 
and 84 from in-vitro matured 
oocytes) 
No. of embryo developed 61 
68 (13 from in-vivo  mature 
and 55 from in-vitro 
matured) 
No. of transferred embryos 56 64 
Mean ± SD of transferred 
embryo 1.1±8.8 1.5±1.12 (P value< 0.05) 
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No difference was observed in implantation rate which was 12.5% 
for both groups. Pregnancy rate was significantly higher in IVM group than 
the control group which was (21.9%, 18.9% respectively; P < 0.05). The 
percentage of embryo transfer cancellation was significantly higher in the 
control group than the IVM group which was (27.45%, 21.9%; P < 0.05) as 
shown in table (3.6).In IVM group, 32 (78.04 %) cycles had transfer out of 
the 41 cycles, in which 4 (12.5%) of  the embryos were derived from only in-
vivo matured oocytes, 16 (50%) embryos were derived from both in-vivo and 
in-vitro matured oocytes, and 12 (37.5%) embryos were derived from only 
in-vitro matured oocytes with implantation rate (7.7%). 
Figure (3.3) Type of Embryos Transferred in IVM Group 
 
From 7(21.9 %) clinical pregnancy, 4(12.5%) of them ended in 
abortion before 8 weeks and 3(9.37%) ongoing pregnancy; two singleton and 
one twin pregnancy ended with labour of  four healthy babies.In control 
group, 37(72.55%) cycles had transfer out of 51 cycles, in which from 
7(18.92%) clinical pregnancies again 4(10.81%) ended in abortion before 8 
weeks and 3( 8.1%) ongoing pregnancies with three singleton ended with 
labour of  three healthy babies. The percentage of abortion and ongoing 
pregnancies were compared between both groups and show no significant 
difference with p value (0.11, 0.22) respectively. 
 
Figure (3.4) Percentage of Abortion and Ongoing Pregnancy in Control and IVM Group 
 
 
 
 
 
0% 50% 100%
embryo transfer 12,50% 50% 37,50% 
emryos derived from in-
vivo matured oocytes
embryos derived from in-
vivo and in-vitro matured
oocytes
10,81% 
8,10% 
81,09% 
control group abortion
ongoing
pregnancy
no clinical
pregnancy
12,50
% 9,37
% 
78,13
% 
IVM group 
abortion
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 Micrograph(1): Stages of oocyte maturation, fertilized oocytes and 
embryo development.(A)Metaphase II Oocytes (400X), (B) Prophase I 
Oocyte (400x), (C) Metaphase I Oocyte (400x) (D) Fertilized In-vivo 
Matured Oocyte (400x), (E) Fertilized In-vitro Matured Oocyte (400x), (F) 
Day 2 High-quality Embryo Derived from In-vitro Matured Oocyte (200x), 
(G) Day 2 Low-quality Embryo Derived from In-vitro Matured Oocytes 
(200x), (H) Day 2 Low-quality Embryo Derived from In-vitro Matured 
Oocytes (200x), (I) Day 3 Low-quality Embryo Derived from In-vitro 
Matured Oocyte (200x), (J) Day 3 High-quality Embryo Derived from In-
vitro Matured Oocyte (200x), (K) Day 3 Low-quality Embryo Derived from 
In-vitro Matured Oocyte (200x), (L) Day 2 High-quality Embryo Derived 
from In-vivo Matured Oocyte (200x), (M) The Low-quality Embryos 
Derived from In-vivo Matured Oocytes in Day 2 (200x), (N) Day3 Low-
quality  Derived from In-vivo Matured Oocyte (200x), (O)  Day3 High-
quality Derived from In-vivo Matured Oocyte (200x). 
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Discussion 
In a stimulated cycle, an administered pharmacological dose of 
gonadotropin creates a supra-physiologic hormonal environment and induces 
simultaneous growth of a cohort of large and small follicles. The 
heterogeneity of the oocyte population at the time of HCG administration 
leads to retrieval of oocytes at different stage of maturation.The present 
study is designed to assess the developmental potential and clinical 
implications of IVM of immature oocytes retrieved from controlled ovarian 
stimulation for IVF/ICSI cycles, specifically investigating 24 hours of IVM 
with subsequent second day injection of matured oocytes. The overall 
retrieved oocytes were 472,from which 37.92% were M II stage and 27.33% 
were M I stage and 26.31% were in P I. The percentage of retrieved mature 
oocytes was lower than the results reported by other studies(Kim et al. 2000; 
Patricial et al. 2003; Strassburger et al. 2004). One explanation for this could 
be thatthe patients included were poor responders. Various studies have 
revealed the benefit of 24 hours IVM of immature oocytes from stimulated 
cycles (Patricial et al., 2003; Reichman et al., 2010; de Almeida et al., 2010). 
The present study showed that the rate of in-vitro maturation of M I stage 
oocytes were 65.38%  which was lower than the rates of some other studies  
(Reichman et al., 2010, de Almeida et al., 2010) in which their results 
showed (78.2% and 75.8%, respectively) even higher rates than the results of 
(Patricial et al., 2003) which was (63.2%)  reported. In the same way, the 
rate of matured P I stage oocytes were 60% which is higher than the results 
of (Patricial et al., 2003; Riechman et al., 2010) which was (38.6% and 
35.1%) respectively, and lower than the (72.7% and 70%) which was found 
by (de Almeida et al., 2010; Farsi et al., 2011). In-vivo oocyte meiotic 
resumption requires intimate paracrine and autocrine signaling between the 
oocyte and its surrounding granulosa and cumulus cells (Sun et al., 2009). 
ICSI involves the removal of cumulus and corona cells shortly after oocyte 
retrieval in order to make a determination of nuclear maturity, as it is 
difficult to identify nuclear maturity under the microscope with the cumulus 
–oocyte-complex intact (Cha and Chian, 1998). Removing cumulus cells, 
however, disrupts signaling pathways between those oocyte discovered to be 
immature and their surrounding cells. Cumulus cells share an integral role in 
meiotic arrest via gap-junction mediated signaling and maintenance of 
oocyte cAMP levels, while also exerting stimulatory effects on nuclear and 
cytoplasmic maturation, as evidenced by higher rates of maturation (Goud et 
al., 1998; Sun et al., 2009). In order to analyze the literature regarding IVM 
of immature oocytes, it is critical to note whether cumulus complexes are left 
intact or are stripped prior to placement in culture media. In this study, 
cumulus were stripped partially to confirm polar body emission and to 
perform ICSI subsequently.The present study showed lower fertilization 
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rates of in-vitro matured oocytes than the in-vivo matured oocytes which was 
similar to the previous studies (De Vose et al., 1999; Kim et al., 2000; Aycan 
et al., 2003; Behr et al., 2004; Strassburger et al., 2004; de Almeida et al., 
2010; Riechman et al., 2010).The reduced fertilization rate of in-vitro 
matured oocytes can be explained by the cytoplasmic immaturity of these 
oocytes in contrast to their nuclear maturation. (Eppig, 1996; Heikinheimo 
and Gibbons, 1998; Trounson et al., 2001; Combelles et al., 2002).In 
comparing the rates of high-quality embryos between in-vivo matured 
oocytes and in-vitro matured oocytes the results of this study show that high-
quality embryos are higher significantly in the in-vitro matured oocytes 
which differs from the results of others studies (Strassburger et al., 2004; 
Farsi et al., 2011) that show no significant difference between in-vivo 
matured and in-vitro matured  oocytes in regard to the number of 
blastomeres, similarly, (de Vose et al., 1999) found no significant difference 
in excellent and fair quality embryos but significantly higher good quality 
embryos in in-vivo matured oocytes, while a study by (de Almeida et al., 
2010) report that the development of high-quality embryos  are significantly 
higher in the in-vivo matured oocytes.In the present study a comparison were 
made between the implantation rate, and the clinical pregnancy rate between 
control and IVM groups in order to evaluate the usefulness of rescued IVM 
of immature oocytes retrieved from stimulated cycles. It was found that the 
IVM of immature oocytes showed lower fertilization rate but significant 
increases in the number of embryos available for transfer (1.54 ± 1.12 versus 
1.1 ± 0.88), decreases in embryo transfer cancellation (27.45% versus 
21.9%) as in a study conducted by (de Almeida et al., 2010) which showed 
(2.35 versus 1.87) and (14.5% versus 6.36%) respectively. This study also 
showed  increases in clinical pregnancy rate (21.9% versus 18.9%) but no 
significant difference is reported in both studies by (de Almeida et al., 2010; 
Reichman et al., 2010), and no significant difference in the  implantation rate 
as this study showed to be (12.5%) for both group which was compatible 
with (de Almeida et al., 2010) results. In 12(37.5%) of IVM cycles, embryos 
derived from in-vitro matured oocytes were only available for transfer and 
their implantation rate was (7.7%), which only two patients  conceived but 
pregnancy terminated with abortion , and this result is higher than (4.7%) 
reported by (de Almeida et al., 2010), (4%) as reported by (Shu et al., 2007) 
and (zero) by (Reichman et al., 2010) and lower than the results of (Liu et 
al., 2003) which was 2 singleton and one twin pregnancy when only embryos 
derived from in-vitro matured oocytes were transferred in eight cycles.The 
results showed that human immature oocytes recovered from stimulated 
cycles can be matured, fertilized and developed in-vitro but they have lower 
fertilization rate than the in-vivo matured oocytes. Embryos derived from in-
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vitro matured oocytes may contribute to the better outcome in poor 
responder cycles. 
 
Conclusion 
The results show that human immature oocytes recovered from 
stimulated cycles can be matured, fertilized and developed in-vitro but they 
have lower fertilization rate than the in-vivo matured oocytes. Embryos 
derived from in-vitro matured oocytes may contribute to the better outcome 
in poor responder cycles. 
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